Group 1 - The company successfully completed the recruitment of 104 patients for the Phase III clinical trial of IMM01 (Tadapaximab) for first-line treatment of chronic myelomonocytic leukemia (CMML) by December 31, 2025, and expects to complete the recruitment of 132 patients needed for interim analysis by the end of March 2026 [1] - The board confirmed that the company's business operations and clinical development remain normal, with no significant adverse changes in the business operations and financial status [1] Group 2 - IMM01 (Tadapaximab) is an innovative targeted CD47 molecule and the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages through a dual mechanism [2] - The product has received orphan drug designation from the U.S. Food and Drug Administration for first-line treatment of CMML in combination with Azacitidine in November 2023 [2] - The company holds global intellectual property and commercialization rights for IMM01 (Tadapaximab), with a patent family that includes granted patents in China, the United States, Japan, and the European Union [2]
宜明昂科-B：业务营运及临床开发维持正常